The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country [0.03%]
PSMA PET/CT的应用可改善生化复发前列腺癌挽救性放疗男性患者的总体生存：来自一个国家的真实世界数据
Anna W Mogensen,Christian Torp-Pedersen,Mette Nørgaard et al.
Anna W Mogensen et al.
International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane antigen (PSMA) PET/CT has demonstrated high s...
Johannes Czernin
Johannes Czernin
Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma [0.03%]
荧光PARP1抑制剂作为诊断基底细胞癌分子对比剂的转化潜力
Miriam Ricanati,Ucalene Harris,Neil M Neumann et al.
Miriam Ricanati et al.
Basal cell carcinoma (BCC), the most common skin cancer, typically requires biopsy for definitive diagnosis. Reflectance confocal microscopy is a noninvasive rule-out test, but the lack of nuclear contrast in BCC often leads to missed diagn...
Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024 [0.03%]
2024年SNMMI人工智能工作组放射组学挑战总结报告
Ronald Boellaard,Arman Rahmim,Jacoba J Eertink et al.
Ronald Boellaard et al.
In medical imaging, challenges are competitions that aim to provide a fair comparison of different methodologic solutions to a common problem. Challenges typically focus on addressing real-world problems, such as segmentation, detection, an...
Evaluation of 134Ce/134La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer [0.03%]
评价134Ce/134La-PSMA-617用于前列腺癌PET显像和Auger电子治疗的效果
Kondapa Naidu Bobba,Anju Wadhwa,Anil P Bidkar et al.
Kondapa Naidu Bobba et al.
The 134Ce/134La radionuclide pair has been proposed as a PET imaging surrogate for targeted α-radiotherapeutics. 134Ce decays to 134La via electron capture, emitting Auger electrons (AEs), which could be used for targeted radionuclide ther...
Radiopharmaceutical Therapy: Balancing Absorbed Dose and Antitumor Immunity [0.03%]
放射性药物治疗：吸收剂量与抗肿瘤免疫的平衡
Jiangtao Yue,Yue Zhang,Yue Miu et al.
Jiangtao Yue et al.
Preirradiation of Spheroids with 225Ac-Trastuzumab Improves Penetration of 225Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails [0.03%]
用225Ac-曲妥单抗预辐照类球体可改善225Ac-脂质体制剂的渗透性并有助于MIRDCell预测药物鸡尾酒的反应
Hima Tallam,Rajiv Nair,Aira Sarkar et al.
Hima Tallam et al.
This investigation examined the factors involved in predicting the responses of micrometastases to targeted 225Ac-based therapies and in optimizing these therapies through the use of cocktails of radiopharmaceuticals (RPTs). Methods: MIRDce...
Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [18F]FGln and [18F]FDG [0.03%]
基于[18F]FDG和[18F]FGln的双示踪剂PET显像：原理验证性研究
Daniel Kwon,Elizabeth J Li,Christina Dulal et al.
Daniel Kwon et al.
Current protocols necessitate imaging 2 18F-labeled tracers in separate sessions. Herein, we report on the development and testing of a protocol that sequentially images 2 18F-labeled tracers-18F-(2S,4R)4-fluoroglutamine, commonly known as ...
Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition [0.03%]
阿尔茨海默病的影像学和流体生物标志物：互补而非竞争
Alexander Drzezga,Henryk Barthel
Alexander Drzezga
With the introduction of the new causal amyloid targeting therapies, the role of biomarker-assisted diagnosis of Alzheimer disease (AD) has received a further boost. In addition to the well-established gold standard, amyloid PET imaging, ce...
A New Dawn [0.03%]
新的黎明
Victor L Villemagne
Victor L Villemagne